Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis

被引：6

作者：

Zhou, Xueyin ^{[1
,2
]}

Cao, Jiasheng ^{[2
,3
]}

Topatana, Win ^{[3
]}

Xie, Tianao ^{[4
]}

Chen, Tianen ^{[2
,3
]}

Hu, Jiahao ^{[2
,3
]}

Li, Shijie ^{[2
,3
]}

Juengpanic, Sarun ^{[3
]}

Lu, Ziyi ^{[3
,5
]}

Zhang, Bin ^{[2
,3
]}

Wang, Kaitai ^{[1
]}

Feng, Xu ^{[2
,3
]}

Shen, Jiliang ^{[2
,3
]}

Chen, Mingyu ^{[2
,3
]}

机构：

[1] Wenzhou Med Univ, Sch Med, Wenzhou 325035, Zhejiang, Peoples R China

[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China

[3] Zhejiang Univ, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China

[4] Guangzhou Med Univ, Clin Sch 3, Dept Clin Med, Guangzhou 511436, Peoples R China

[5] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China

来源：

IMMUNOTHERAPY | 2023年 / 15卷 / 05期

关键词：

biomarker; hepatocellular carcinoma; meta-analysis; PD-L1; systematic review; UROTHELIAL CARCINOMA; EXPRESSION; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.2217/imt-2022-0168

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim:To determine if PD-L1 can be used as a biomarker to predict the efficacy of anti-PD-1/PD-L1 inhibitors in hepatocellular carcinoma (HCC). Methods:Relevant studies from a specific search of the four databases from October 2014 to December 2022 were included in this meta-analysis. Results:Higher PD-L1 expression levels were associated with a higher objective response rate (ORR). Higher PD-L1 expression levels on tumor cells and tumor proportion score were associated with higher ORR. PD-L1 was capable of predicting the effectiveness of nivolumab. Dako 28-8 is a promising assay for HCC. Conclusion:PD-L1 is a predictive biomarker for ORR in HCC. Tumor proportion score and PD-L1 expression levels on tumor cells are potential scoring algorithms.

引用

页码：353 / 365

页数：13

共 50 条

[1] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Yuwei Liu
Jiahui Pan
Fangbo Gao
Wentao Xu
Hongyu Li
Xingshun Qi
[J]. Advances in Therapy, 2023, 40 : 521 - 549
[2] Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Quan Rao
Min Li
Wei Xu
Kai Pang
XiaoBo Guo
Dong Wang
Jun Liu
Wei Guo
ZhongTao Zhang
[J]. Hepatology International, 2020, 14 : 765 - 775
[3] Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Rao, Quan
Li, Min
Xu, Wei
Pang, Kai
Guo, XiaoBo
Wang, Dong
Liu, Jun
Guo, Wei
Zhang, ZhongTao
[J]. HEPATOLOGY INTERNATIONAL, 2020, 14 (05) : 765 - 775
[4] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Liu, Yuwei
Pan, Jiahui
Gao, Fangbo
Xu, Wentao
Li, Hongyu
Qi, Xingshun
[J]. ADVANCES IN THERAPY, 2023, 40 (02) : 521 - 549
[5] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen, Wen
Zhang, Yong
Zhang, Hua
Chen, Yingshuang
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 969 - 978
[6] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen Wen
Yong Zhang
Hua Zhang
Yingshuang Chen
[J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 969 - 978
[7] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
Yang, Yao
Chen, Dongbo
Zhao, Bigeng
Ren, Liying
Huang, Rui
Feng, Bo
Chen, Hongsong
[J]. CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
[8] Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis
Cheng, Yang
Wang, Chong
Wang, Yan
Dai, Li
[J]. FUTURE ONCOLOGY, 2021, 18 (02) : 261 - 273
[9] Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors in the treatment of hepatocellular carcinoma: A meta-analysis and systematic review
Zhang, Baoyan
Su, Linfeng
Lin, Yonghua
[J]. ONCOLOGY LETTERS, 2024, 28 (01)
[10] Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Xie, Tong
Zhang, Zhening
Zhang, Xiaotian
Qi, Changsong
Shen, Lin
Peng, Zhi
[J]. FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →